AngioDynamics pairs a bullish technical breakout and a three-quarter earnings beat streak — with another print in just 10 days — against a business quality score that sits below the engine's floor and options positioning that is unusually skewed toward puts, making this a momentum-and-catalyst trade rather than a quality-driven one.
Thesis pillars
- Quality Below Floor→Stable
- Bullish Breakout Setup↑Improving
- Earnings Beat Streak↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Jul 14, 2026
AngioDynamics, Inc. (ANGO) Stock Analysis
Inst Constrain edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $12.13: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
AngioDynamics, based in Latham, New York, designs and sells medical devices for cardiovascular disease and cancer treatment through two segments, Med Tech and Med Device. Med Tech includes the Auryon atherectomy laser, AlphaVac and AngioVac thrombectomy systems and the NanoKnife... Read more
Sell if holding. Engine safety override at $12.13: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 68d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About AngioDynamics, Inc.
About AngioDynamics, Inc.
AngioDynamics, founded in Queensbury, New York in 1988 and headquartered in Latham, New York, sells medical devices for cardiovascular disease and cancer treatment through two segments, Med Tech and Med Device. Fiscal 2026 ended May 31, 2026, and international sales increased 9% in the year, partly because of divestitures and product discontinuations. All products discussed in the filing have FDA clearance in the United States, while international clearances vary by product and jurisdiction.
Med Tech holds the newer platforms. The Auryon Atherectomy System uses a 355nm laser to treat peripheral artery disease. The Thrombus Management portfolio includes AlphaVac, whose F18 system is indicated for pulmonary embolism, AngioVac venous drainage cannulas and Uni-Fuse thrombolytic catheters. The NanoKnife IRE Ablation System received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024 and BSI approval for the MDR CE mark in February 2026, covering pancreas, kidney, liver or prostate tumors. Med Device sells angiographic catheters, guidewires, drainage catheters, micropuncture kits and implantable ports such as SmartPort, used mainly in cancer treatment protocols. Portfolio pruning has been active: the dialysis and BioSentry businesses were sold to Merit Medical Systems in June 2023, the PICC and Midline businesses to Spectrum Vascular in February 2024, and the RadioFrequency Ablation and Syntrax lines were discontinued as of February 29, 2024.
Show full overview
Distributor dependence is the sharpest lens. Outside North America, AngioDynamics relies heavily on third-party distributors, including in China, Japan, Brazil, the Middle East and many European countries, and international distributors accounted for approximately 75% of international revenues in fiscal 2026. Distributors may also sell competing products or fail to remain financially viable, so the loss of those relationships could cost significant revenue. Leadership is also changing: in an October 2026 Form 8-K, the Board appointed Eric Honroth, formerly President Life Science at Getinge AB, as President and CEO effective November 2, 2026, succeeding James C. Clemmer, who has led the company since April 2016.
See also: Healthcare · Medical Instruments & Supplies
From AngioDynamics, Inc.'s most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — AngioDynamics, Inc.
Material events (past 30 days)
- 8K Oct 8, 2026 MEDIUM Item 5.02: Board appointed Eric Honroth (ex-President Life Science, Getinge) as President and CEO effective Nov 2, 2026, succeeding retiring CEO James Clemmer (CEO since April 2016). Clean handoff; no disagreement cited.
Latest news
- NEWS AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE — fiscal.ai Oct 21, 2026 positive
- NEWS AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinom — benzinga Oct 21, 2026 positive
- NEWS AngioDynamics Says Humana Updates Medicare Advantage Policy To Cover NanoKnife For Eligible Prostate And Liver Cancer Pa — benzinga Oct 14, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18 — benzinga Oct 13, 2026 neutral
- NEWS AngioDynamics Stock Is Falling Thursday: What's Going On? — benzinga Oct 8, 2026 negative
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerinternational distributors10-K Item 1A: 'International distributors accounted for approximately 75% of international revenues for the fiscal year ended May 31, 2026.'
Material Events(8-K, last 90d)
- 2026-10-08Item 5.02MEDIUMBoard appointed Eric Honroth (ex-President Life Science, Getinge) as President and CEO effective Nov 2, 2026, succeeding retiring CEO James Clemmer (CEO since April 2016). Clean handoff; no disagreement cited.SEC filing →
- 2026-10-08Item 1.01LOWCompany entered an employment agreement on Oct 3, 2026 with Eric Honroth to serve as President and CEO; terms described under Item 5.02, filed as Exhibit 10.1.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.13: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.28. Score 5.9/10, moderate confidence.
Analyst target: $16.79 (+38.4% upside). Prior stop was $11.28. Stop-loss: $11.28.
Quality below floor (4.0 < 4.0).
AngioDynamics, Inc. trades at a P/E of N/A (forward -107.0). TrendMatrix value score: 9.1/10. Verdict: Sell.
10 analysts cover ANGO with a consensus score of 4.1/5. Average price target: $20.
What does AngioDynamics, Inc. do?AngioDynamics, based in Latham, New York, designs and sells medical devices for cardiovascular disease and cancer...
AngioDynamics, based in Latham, New York, designs and sells medical devices for cardiovascular disease and cancer treatment through two segments, Med Tech and Med Device. Med Tech includes the Auryon atherectomy laser, AlphaVac and AngioVac thrombectomy systems and the NanoKnife IRE ablation system; Med Device covers angiographic catheters, guidewires, drainage products and ports. Outside North America it relies on third-party distributors for about 75% of international revenue.